• Profile
Close

Efficacy and safety of topical timolol for the treatment of infantile hemangioma in the early proliferative stage: A randomized clinical trial

JAMA May 25, 2021

Muñoz-Garza FZ, Ríos M, Roé-Crespo E, et al. - In this multicenter, randomized, double-blind, placebo-controlled, phase 2a pilot clinical trial involving 69 patients [mean (SD) age 48.4 (10.6) days], researchers tested the safety and effectiveness of timolol maleate solution, 0.5%, for the early treatment of infantile hemangioma (IH) in infants younger than 60 days. The sample consisted of patients aged 10 to 60 days with focal or segmental hemangiomas (superficial, deep, mixed, or minimal/arrested growth). Study participants were randomly assigned to receive either 0.5% topical timolol maleate solution or a placebo twice daily for 24 weeks. At 24 weeks, there were no significant differences between timolol and placebo in terms of complete or nearly complete IH resolution. At week 4, there was a significant improvement in lesion color in the timolol group, and topical timolol was well tolerated. When given during the early proliferative stage, topical timolol appears to be well tolerated in the treatment of early proliferative IH, but it appears to have minimal benefit in terms of resolving lesions.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay